- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02624999
Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck
An Individualized Cancer Vaccine for Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
All accrued subjects will be randomized 2:1 to AlloVax™ (CRCL + AlloStim™) immunotherapy vs. standard chemotherapy. AlloVax™ is an experimental individualized therapeutic vaccine shown to be active in this study population.
The standard chemotherapy arm (Arm 1) will receive up to six three-week cycles of chemotherapy consisting of cisplatin on day 0 of the 3-week cycle at dose 80-100 mg/m2 IV followed by 1000 mg/m2 IV flurouracil (5FU) on days 1-4 of the cycle.
The immunotherapy arm (Arm 2) will receive immunotherapy (AlloVax™) twice a week for 4 weeks and then every 4 weeks for an additional 12 weeks.
The study is designed and powered to determine if AlloVax™ is not inferior to the active chemotherapy control.
Undersøgelsestype
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Bangkok, Thailand, 10400
- National Cancer Institute of Thailand
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Adult males and female subjects aged 18 years or older at screening visit.
- Histopatholologically or cytologically confirmed diagnosis of locoregionally recurrent unresectable or previously untreated metastatic SCCHN.
- Tumor lesion safely accessible for biopsy or surgical excision resulting in a minimum of 0.2 g of tumor sample for CRCL processing.
- Subjects must have measurable disease according to revised RECIST v.1.1 guidelines.
- Eastern Cooperative Oncology Group (ECOG) ≤1.
- Subjects must be screened to be negative for Human Immunodeficiency Virus 1 (HIV1), HBsAg, Hepatitis C (HCV) and Rapid Plasma Reagin (RPR,syphilis).
- Subjects must have adequate organ function including: (WBC >3000/mm3, Platelets >100,000/mm3, Absolute neutrophil count ≥ 1,500/mm³, Hemoglobin ≥ 10.0 g/dL (transfusion allowed)), Hepatic (Serum Total bilirubin < 2 x ULN mg/dL, Alanine transaminase (ALT) (SGPT) / Aspartate aminotransferase (AST) (SGOT) ≤3 x upper limit of normal (ULN)), Renal: Serum creatinine (SCR) <2.0 x ULN, or, Creatinine clearance (CCR) >30 mL/min.
- Pre-study EKG without significant abnormalities.
- Women of child-bearing potential must have a negative urine or serum pregnancy test result within 72 hours prior to the start of study drug administration.
- If child producing potential age, must agree to use contraception or avoidance of pregnancy measures while enrolled on study and receiving the experimental product.
- Ability to understand the study, its inherent risks, side effects and potential benefits and be able to give written informed consent to participate.
Exclusion Criteria:
- Clinical evidence or radiological evidence of brain metastasis.
- Treated for another primary cancer within 2 years prior to signing inform consent form.
- Any concomitant anticancer therapies.
- History of severe hypersensitivity to monoclonal antibody drugs or any contraindication to any of the study drugs.
- Concomitant active autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, autoimmune thyroid disease, uveitis).
- Prior experimental therapy or cancer vaccine treatment (e.g., dendritic cell therapy, heat shock vaccine).
- Clinical requirement for systemic steroids or immunosuppressive therapy, including: cyclosporine, antithymocyte globulin, or tacrolimus within 1 month prior to signing inform consent form.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, requiring parenteral antibiotics, symptomatic congestive heart failure, severe myocardial insufficiency, cardiac arrhythmia. All infections must be resolved and the subject must remain a febrile for seven days prior to being placed in the study.
- History of blood transfusion reactions.
- Psychiatric or addictive disorders or other condition that, in the opinion of the investigator, would preclude study participation.
- Female subject is pregnant or breast-feeding
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Immunotherapy
Subjects in this arm will receive immunotherapy (AlloVax™: CRCL + AlloStim™) twice a week for 4 weeks and then every 4 weeks for an additional 12 weeks
|
AlloVax™ combines an anti-tumor effect of mini-transplant procedures with patient specific tumor antigens
Andre navne:
|
Aktiv komparator: Standard chemotherapy
Subjects in this arm will receive up to six three-week cycles of chemotherapy consisting of cisplatin on day 0 of the 3-week cycle at dose 80-100 mg/m2 IV followed by 1000 mg/m2 IV 5FU on days 1-4 of the cycle
|
Subjects in the chemotherapy arm will receive up to 6 cycles of cisplatin on day 0 of the 3-week cycle at dose of 80-100 mg/m2 IV and 1000 mg/m2 IV 5FU on days 1-4 of the cycle
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Safety and tolerability (vital signs, physical examination, clinical laboratory profile, adverse events assessed by CTCAE v4.0 and dose limiting toxicity (DLT))
Tidsramme: 119 days
|
Whether AlloVax™ is less toxic than chemotherapy.
will be evaluated on the basis of the following parameters: vital signs, physical examination, clinical laboratory profile, adverse events assessed by CTCAE v4.0 and dose limiting toxicity (DLT)
|
119 days
|
Overall Survival
Tidsramme: 119 days
|
Whether AlloVax™ is not inferior to the active chemotherapy control (from time of randomization).
Subjects are followed for survival during the trial and as long as they are alive after the last study treatment through follow-up
|
119 days
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Health related Quality of Life (HRQoL)
Tidsramme: 119 days
|
QLQ-C30 and QLQ-H&N35 questionnaires
|
119 days
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
RECIST
Tidsramme: 119 days
|
Response and correlation with pathology assessment
|
119 days
|
Immune-Related Response Criteria (irRC)
Tidsramme: 119 days
|
Response and correlation with pathology assessment
|
119 days
|
Immune response in the treatment arm
Tidsramme: 119 days
|
Correlation of OS with immune response
|
119 days
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Michael Har-Noy, Dr., CEO & CTO
Datoer for undersøgelser
Studer store datoer
Studiestart (Forventet)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ITL-020-HENK-VAXPII
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med AlloVax™
-
Immunovative Therapies, Ltd.Trukket tilbageHepatocellulært karcinomIsrael
-
Immunovative Therapies, Ltd.AfsluttetAvanceret hepatocellulært karcinom hos voksneThailand
-
Immunovative Therapies, Ltd.AfsluttetPlanocellulært karcinom i hoved og hals | Kræft i hoved og halsThailand
-
BaroNova, Inc.Afsluttet
-
London Health Sciences CentreUniversity of Western Ontario, Canada; Synaptive MedicalUkendtHjerneskade, kronisk | Cerebellar Cognitive Affective Syndrome | Cerebellar mutisme
-
Medtronic CardiovascularMedtronicAfsluttetAortastenoseNew Zealand, Det Forenede Kongerige, Australien
-
Gülçin Özalp GerçekerAfsluttetKateterkomplikationer | KateterlækageKalkun
-
CereVasc IncAlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting...RekrutteringHydrocephalus | Hydrocephalus, KommunikerendeArgentina
-
Asklepios Kliniken Hamburg GmbHUniversity of KielAfsluttetLuftvejsstyring | Larynx maske Airway | Fibreoptisk intubation
-
Medtronic CardiovascularAktiv, ikke rekrutterendeAortaaneurismeTyskland, New Zealand, Forenede Stater, Holland, Schweiz, Det Forenede Kongerige, Spanien, Australien, Italien, Sverige, Frankrig, Østrig, Slovakiet